Entrada Therapeutics Q3 net loss narrows 10% to $39.74 million
TRDA•Entrada Therapeutics’ third-quarter 2026 net loss narrowed 10% to $39.74 million, while collaboration revenue fell 44% to $905,000. The company had $193.02 million in cash, cash equivalents and marketable securities, which it said is expected to fund operations into the fourth quarter of 2027.
1. Quarterly results and outlook
Entrada Therapeutics reported a third-quarter 2026 net loss of $39.74 million, down 10% year over year, and collaboration revenue of $905,000, down 44%. Research and development expenses fell 16% to $32.37 million, driven by lower Duchenne preclinical and facility-related costs. The company said its $193.02 million in cash, cash equivalents and marketable securities is expected to support its runway into the fourth quarter of 2027.
2. Clinical trial updates
Entrada said ELEVATE-44-201 Cohort 1 open-label data are expected by year-end 2026, with Cohort 2 results due in the first quarter of 2027. ELEVATE-45-201 Cohort 1 met its safety and tolerability objectives, and Cohort 2 data are expected in the first half of 2027.
